Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yano, B. L.
Right arrow Articles by Reasor, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yano, B. L.
Right arrow Articles by Reasor, M. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences 65, 288-298 (2002)
Copyright © 2002 by the Society of Toxicology


SAFETY EVALUATION

Spinosad Insecticide: Subchronic and Chronic Toxicity and Lack of Carcinogenicity in Fischer 344 Rats

B. L. Yano*,1, D. M. Bond*, M. N. Novilla{dagger}, L. G. McFadden* and M. J. Reasor{ddagger}

* Toxicology and Environmental Research and Consulting, The Dow Chemical Company, 1803 Building, Midland, Michigan, 48674; {dagger} Lilly Research Laboratories, Division of Eli Lilly and Company, Greenfield, Indiana 46268; and {ddagger} Department of Pharmacology and Toxicology, West Virginia University, Morgantown, West Virginia, 26506

Spinosad is an insecticide derived from a naturally occurring bacterium via fermentation. The toxicity of spinosad was characterized in subchronic and chronic toxicity/oncogenicity studies conducted according to standard toxicology regulatory guidelines. Subchronic toxicity was evaluated in groups of 10 Fischer 344 rats/sex given feed containing 0, 0.05, 0.1, 0.2, or 0.4% spinosad (Study 1) or 0, 0.003, 0.006, 0.012, or 0.06% spinosad (Study 2) for 13 weeks. Lower body weights and increased mortality occurred in rats given 0.4% spinosad. Microscopic effects were observed in the adrenal glands, liver, lymphoid cells, reproductive tissues, kidney, thyroid, stomach, lung, and skeletal muscle of rats given >= 0.05% spinosad, and consisted primarily of vacuolation of cells; however, degenerative, regenerative, and/or inflammatory changes were also noted in some tissues. Vacuolation within a number of tissues was ultrastructurally characterized by an increase in size and number of lysosomes that contained extensive membranous whorls consistent with phospholipidosis. The no observed effect level (NOEL) in the 13-week studies was 0.012% (24 mg/kg/day) spinosad. Chronic toxicity and oncogenicity were evaluated in groups of 60 Fischer 344 rats/sex given feed containing 0, 0.005, 0.02, 0.05, or 0.1% spinosad for up to 2 years. Rats given 0.1% spinosad for 1 year had microscopic effects similar to those observed in the subchronic studies. Vacuolation and inflammation of the thyroid gland also occurred in rats given 0.05% spinosad for 1 year. Excessive mortality occurred in rats from the oncogenicity study given 0.1% spinosad by 21 months, and surviving rats were euthanized because the maximum tolerated dose had been exceeded. Rats given 0.05% spinosad for 2 years had vacuolation and/or inflammation involving the thyroid, lymphoid tissue, and lung. Rats given 0.05% spinosad had similar numbers of neoplasms as control rats, indicating that spinosad was not carcinogenic at dose levels up to 0.05%. The NOEL at 2 years was 0.005% (2.4 mg/kg/day) spinosad.

Key Words: spinosad; rat; toxicity; carcinogenicity.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Toxicol PatholHome page
S. L. Vonderfecht, M. L. Stone, R. R. Eversole, M. F. Yancey, M. R. Schuette, B. A. Duncan, and J. A. Ware
Myopathy Related to Administration of a Cationic Amphiphilic Drug and the Use of Multidose Drug Distribution Analysis to Predict its Occurrence
Toxicol Pathol, April 1, 2004; 32(3): 318 - 325.
[Abstract] [PDF]


Home page
Toxicol PatholHome page
D. G. Rudmann, M. E. Mcnerney, S. L. Vandereide, J. K. Schemmer, R. R. Eversole, and S. L. Vonderfecht
Epididymal and Systemic Phospholipidosis in Rats and Dogs Treated with the Dopamine D3 Selective Antagonist PNU-177864
Toxicol Pathol, April 1, 2004; 32(3): 326 - 332.
[Abstract] [PDF]


Home page
Toxicol SciHome page
T. R. Hanley Jr., W. J. Breslin, J. F. Quast, and E. W. Carney
Evaluation of Spinosad in a Two-Generation Dietary Reproduction Study Using Sprague-Dawley Rats
Toxicol. Sci., May 1, 2002; 67(1): 144 - 152.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
K. E. Stebbins, D. M. Bond, M. N. Novilla, and M. J. Reasor
Spinosad Insecticide: Subchronic and Chronic Toxicity and Lack of Carcinogenicity in CD-1 Mice
Toxicol. Sci., February 1, 2002; 65(2): 276 - 287.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.